WebJan 12, 2010 · Thurlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D and Colleoni M et al (2009). Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 113 (1): 137–144 WebApr 14, 2024 · Background Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country, phase III trial that randomized 9776 women for the use of hormonal therapy. Of these 2754 were Dutch …
Books by Thurlimann Book Depository
WebMar 18, 2015 · Tumor specimen of 2284 female patients with primary breast cancer was classified into five subtypes. Distant recurrence-free survival at 3 years was most unfavorable in Her2-enriched (66.8 %), triple negative (75.9 %), and triple-positive breast cancer (81.7 %). The same subtypes most frequently presented with visceral metastases … WebProfessor Thürlimann is a consultant in breast and gynaecological cancer. His key professional interests are breast cancer, adjuvant therapies, new drugs and international research. dottie bailey state rep
Assessment of letrozole and tamoxifen alone and in sequence for ...
Web3 present and debate the available preclinical and clinical evidence for the use of adjuvant bisphosphonates. This was followed by a questionnaire to all members of the writing committee WebHürlimann was born in Zug, Switzerland. [1] He is a son of the former government and federal councilor (Minister) Hans Hürlimann. [2] He studied philosophy in Zürich and … WebDec 29, 2005 · Methods: The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant … dottie beam eater screws